CompletedNCT00642369
A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
Medication studyAges 18–65China
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- GuangzhouSee all locations and recruitment
Study information
Study start dateMarch 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Guang Dong Provincial Mental Health Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00642369
- Official title
Show the full official title
Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia
Recruitment & locations
CompletedGuangzhou
Questions about this study
Who is behind this study?
The study sponsor is Guang Dong Provincial Mental Health Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including quetiapine fumarate and haloperidol.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity